ZFYVE9

Across TCGA pan-cancer cohorts, ZFYVE9 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ZFYVE9’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ZFYVE9 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ZFYVE9 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where ZFYVE9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZFYVE9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.424	<.001	11	view →
LUAD	Female	III,IV	−0.583	<.001	9	view →
LSCC	Male	All	−0.522	<.001	8	view →
HNSC	Male	All	−0.279	<.001	8	view →
PDAC	All	III,IV	−0.498	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ZFYVE9–CCRCC

Open the CCRCC breakdown →